Johnson & Johnsonvs10x Genomics

JNJ and TXG stock compared: price, dividend, valuation and results, from SEC filings.

TXG

10x Genomics, Inc.

$57.07

Value $7.3B

+2.38%
TXG's page

Johnson & Johnson (JNJ) has a market value of $657B and 10x Genomics (TXG) $7.3B. Over the last year, with dividends, JNJ moved +45.4% and TXG +254.3%. Dividend yield: JNJ 1.94%, TXG none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$657B

    TXG$7.3B

    JNJ is 90 times TXG

  • Revenue, 12 months

    JNJ$99.3B

    TXG$619M

    JNJ is 161 times TXG

  • Net income, 12 months

    JNJ$16.1B

    TXG-$67M

  • Operating margin

    JNJ–

    TXG-11.7%

  • ROIC

    JNJ12.4%

    TXG-7.0%

    19.4 points apart

  • P/E

    JNJ40.8

    TXG–

  • Dividend yield

    JNJ1.9%

    TXG0.0%

    1.9 points apart

  • 5-year return

    JNJ+97.0%

    TXG-64.9%

    161.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+97.0%

TXG-64.9%

010020020222023202420252026
Returns by period
PeriodJNJWith dividendsTXGWith dividends
1 year since November 14, 2025+45.4%Price +42.2%+254.3%Price +254.3%
3 years since November 17, 2023+102.6%+26.5% a yearPrice +86.1%+33.5%+10.1% a yearPrice +33.5%
5 years since November 16, 2021+97.0%+14.5% a yearPrice +71.3%-64.9%-18.9% a yearPrice -64.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonTXG10x Genomics

Valuation

JNJTXG
Valuation
Price$272.70$57.07
Market value$657B$7.3B
Enterprise value (EV)$685B$6.7B
P/E40.8–
P/E, 5-year median21.9–
P/B8.18.7
EV/EBIT38.6–
Free cash flow yield3.1%1.3%

Results and growth

JNJTXG
Results and growth
Revenue, 12 months$99.3B$619M
Net income, 12 months$16.1B-$67M
Free cash flow, 12 months$20.6B$94M
Earnings per share, 12 months$6.59-$0.52
Revenue growth, year on year6.1%5.3%
Revenue growth a year, past+2.7%over 5 years+16.6%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJTXG
Margins and returns on capital
Gross margin67.6%71.9%
Operating margin–-11.7%
Net margin16.2%-10.8%
ROIC12.4%-7.0%
ROE19.7%-8.3%

Balance sheet

JNJTXG
Balance sheet
Cash$17.2B$576M
Total debt$44.7B$76M
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJTXG
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or TXG

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or 10x Genomics?

By market value, Johnson & Johnson ($657B) is about 90.2 times 10x Genomics ($7.3B), at today's prices.

How did JNJ and TXG stock do over the last 5 years?

Since November 16, 2021, JNJ's price moved +71.3% and TXG's -64.9%. With dividends: JNJ +97.0% (+14.5% a year), TXG -64.9% (-18.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or TXG?

The dividend yield at today's price is 1.94% for Johnson & Johnson and none for 10x Genomics. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or 10x Genomics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -10.8% for 10x Genomics, and the operating margin – and -11.7%. Revenue was $99.3B and $619M.

Which is the better investment, Johnson & Johnson or 10x Genomics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.